Letter to the Editor
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry
Eficacia y seguridad de baricitinib en pacientes con artritis reumatoide y respuesta inadecuada a FAME convencionales sintéticos o biológicos: datos de un registro local
Read
1981
Timeswas read the article
644
Total PDF
1337
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 April | 27 | 11 | 38 |
| 2024 March | 66 | 28 | 94 |
| 2024 February | 87 | 25 | 112 |
| 2024 January | 85 | 23 | 108 |
| 2023 December | 64 | 35 | 99 |
| 2023 November | 93 | 43 | 136 |
| 2023 October | 69 | 33 | 102 |
| 2023 September | 132 | 39 | 171 |
| 2023 August | 50 | 21 | 71 |
| 2023 July | 60 | 27 | 87 |
| 2023 June | 74 | 39 | 113 |
| 2023 May | 57 | 24 | 81 |
| 2023 April | 41 | 22 | 63 |
| 2023 March | 69 | 37 | 106 |
| 2023 February | 54 | 28 | 82 |
| 2023 January | 42 | 21 | 63 |
| 2022 December | 68 | 42 | 110 |
| 2022 November | 60 | 38 | 98 |
| 2022 October | 59 | 39 | 98 |
| 2022 September | 65 | 64 | 129 |
| 2022 August | 4 | 3 | 7 |
| 2022 May | 1 | 2 | 3 |
| 2022 April | 2 | 0 | 2 |
| 2022 February | 7 | 0 | 7 |
| 2021 July | 1 | 0 | 1 |
Show all
